Approval · Notice of Compliance 20801 · 2018
COPAXONE: Notice of Compliance 20801
Issued April 26, 2018
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 20801
- Date
- April 26, 2018
- Company
- Teva Canada LimitedToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Updates to mechanism of action, drug interactions, use in pregnancy, and product monograph.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| COPAXONE | Not yet assigned | — |
Medicinal ingredients
- GLATIRAMER ACETATE 20 MG per SYR
- GLATIRAMER ACETATE 40 MG per SYR